News

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014

Read More...

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference

Read More...

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT (formerly RHB-103)

RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine Drug RIZAPORT (formerly RHB-103)   RedHill Biopharma and IntelGenx Submit European Marketing Authorization Application for Migraine drug RIZAPORT (formerly RHB-103) – Hebrew

Read More...

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment

Read More...

RedHill Biopharma to Present at the 7th Annual BioPharm America International Partnering Conference

RedHill Biopharma to Present at the 7th Annual BioPharm America International Partnering Conference

Read More...

RedHill Biopharma to Present at the Rodman and Renshaw 16th Annual Global Investment Conference

RedHill Biopharma to Present at the Rodman and Renshaw 16th Annual Global Investment Conference

Read More...

RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis

RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis   RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis – Hebrew  

Read More...

RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA

RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA   RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study Targeting Broadened H. pylori Indication Authorized by FDA – Hebrew

Read More...

RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101

RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101   RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101 – Hebrew  

Read More...

RedHill Biopharma Reports Results for the Second Quarter of 2014

RedHill Biopharma Reports Results for the Second Quarter of 2014   RedHill Biopharma Reports Results for the Second Quarter of 2014 – Hebrew

Read More...

RedHill Biopharma to Host Second Quarter 2014 Financial Results Conference Call on July 24, 2014

RedHill Biopharma to Host Second Quarter 2014 Financial Results Conference Call on July 24 2014

Read More...

RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON from WILEX AG

RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON from WILEX AG   RedHill Biopharma Acquires Phase II Oncology Drug MESUPRON from WILEX AG – Hebrew

Read More...

RedHill Biopharma Announces Positive Preliminary Pre-Clinical Data with RHB-104 for the Treatment of Type 1 Diabetes

RedHill Biopharma Announces Positive Preliminary Pre-Clinical Data with RHB-104 for the Treatment of Type 1 Diabetes

Read More...

RedHill Biopharma to Present at the 2014 BIO International Convention

RedHill Biopharma to Present at the 2014 BIO International Convention

Read More...

RedHill Biopharma to Present at the Wells Fargo Securities 9th Annual Healthcare Conference

RedHill Biopharma to Present at the Wells Fargo Securities 9th Annual Healthcare Conference

Read More...

RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn’s Program

RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn’s Program   RedHill Biopharma Announces New RHB-104 Patent in Japan and Provides Update on Phase III Crohn’s Program – Hebrew

Read More...

RedHill Biopharma to Present at Jefferies 2014 Global Healthcare Conference

RedHill Biopharma to Present at Jefferies 2014 Global Healthcare Conference

Read More...

RedHill Biopharma Announces FDA Clearance for Phase III Study with RHB-102 Planned to Commence in Q3/2014

RedHill Biopharma Announces FDA Clearance for Phase III Study with RHB-102 Planned to Commence in Q3 2014   RedHill Biopharma Announces FDA Clearance for Phase III Study with RHB-102 Planned to Commence in Q3 2014 – Hebrew

Read More...

RedHill Biopharma and IntelGenx Report Positive RHB-103 Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014

RedHill Biopharma and IntelGenx Report Positive RHB-103 Bioavailability Study Results in Support of Planned European Marketing Application in Q3 2014   RedHill Biopharma and IntelGenx Report Positive RHB-103 Bioavailability Study Results in Support of Planned European Marketing Application in Q3 2014 – Hebrew

Read More...

RedHill Biopharma to Present at the ChinaBio Partnering Forum 2014

RedHill Biopharma to Present at the ChinaBio Partnering Forum 2014

Read More...

RedHill Biopharma Reports Results for the First Quarter of 2014

RedHill Biopharma Reports Results for the First Quarter of 2014   RedHill Biopharma Reports Results for the First Quarter of 2014 – Hebrew

Read More...

RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3 2014

RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3 2014   RedHill Biopharma Reports Successful RHB-102 Bioavailability Clinical Trial and Planned Submission of European Marketing Application in Q3 2014 – Hebrew

Read More...

RedHill Biopharma to Host First Quarter 2014 Financial Results Conference Call on May 1, 2014

RedHill Biopharma to Host First Quarter 2014 Financial Results Conference Call on May 1 2014

Read More...

RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study with RHB-103 (Migraine) to Support European Marketing Application Planned for Q3 2014

RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study with RHB-103 (Migraine) to Support European Marketing Application Planned for Q3 2014   RedHill Biopharma and IntelGenx Announce Commencement of a Bioavailability Study with RHB-103 (Migraine) to Support European Marketing Application Planned for Q3 2014 – Hebrew

Read More...

RedHill Biopharma and IntelGenx Provide an Update on FDA’s Ongoing Review of the NDA for RHB-103 Oral Migraine Film

RedHill Biopharma and IntelGenx Provide an Update on FDA’s Ongoing Review of the NDA for RHB-103 Oral Migraine Film   RedHill Biopharma and IntelGenx Provide an Update on FDA’s Ongoing Review of the NDA for RHB-103 Oral Migraine Film – Hebrew

Read More...

RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application

RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application   RedHill Biopharma Announces Positive European Scientific Advice Meeting Regarding RHB-102 and Plans to Submit a European Marketing Application – Hebrew

Read More...

RedHill Biopharma to Present at the 26th Annual ROTH Conference

RedHill Biopharma to Present at the 26th Annual ROTH Conference

Read More...

RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property

RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property   RedHill Biopharma Provides Update on RHB-102 Development and Intellectual Property – Hebrew

Read More...

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film

RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film   RedHill Biopharma and IntelGenx Submit Response to FDA CRL for RHB-103 Migraine Oral-Film – Hebrew

Read More...

RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill’s RHB-106 Encapsulated Bowel Preparation

RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill’s RHB-106 Encapsulated Bowel Preparation   RedHill Biopharma and Salix Pharmaceuticals Announce Worldwide Exclusive License Agreement for RedHill’s RHB-106 Encapsulated Bowel Preparation – Hebrew

Read More...

RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results

RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results   RedHill Biopharma Reports 2013 Fourth Quarter and Year-End Financial Results – Hebrew

Read More...

RedHill Biopharma and IntelGenx Receive Complete Response Letter from FDA for RHB-103 Oral Film for Acute Migraines

RedHill Biopharma and IntelGenx Receive Complete Response Letter from FDA for RHB-103 Oral Film for Acute Migraines   RedHill Biopharma and IntelGenx Receive Complete Response Letter from FDA for RHB-103 Oral Film for Acute Migraines – Hebrew

Read More...

RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement

RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement   RedHill Biopharma Closes Previously Announced $11.7 Million Private Placement – Hebrew

Read More...

RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement

RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement   RedHill Biopharma Announces Definitive Agreement for $11.7 Million Private Placement – Hebrew

Read More...

RedHill Biopharma Announces Closing of $8.5 Million Private Placements from OrbiMed and Broadfin

Form 6-K RedHill Biopharma Announces Closing of $8.5 Million Private Placements from OrbiMed and Broadfin

Read More...

RedHill Biopharma Provides Update on PK Program in Support of Ongoing RHB-104 Phase III Crohn’s Study

RedHill Biopharma Provides Update on PK Program in Support of Ongoing RHB-104 Phase III Crohn’s Study   RedHill Biopharma Provides Update on PK Program in Support of Ongoing RHB-104 Phase III Crohn’s Study – Hebrew

Read More...

RedHill Biopharma Announces Definitive Agreement for $2.5 Million Private Placement from Broadfin Capital LLC

RedHill Biopharma Announces Definitive Agreement for $2.5 Million Private Placement from Broadfin Capital LLC   RedHill Biopharma Announces Definitive Agreement for $2.5 Million Private Placement from Broadfin Capital LLC – Hebrew

Read More...

RedHill Biopharma Announces Definitive Agreement for $6 Million Private Placement from OrbiMed Israel Partners

RedHill Biopharma Announces Definitive Agreement for $6 Million Private Placement from OrbiMed Israel Partners   RedHill Biopharma Announces Definitive Agreement for $6 Million Private Placement from OrbiMed Israel Partners – Hebrew

Read More...

RedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study

RedHill Biopharma Reports Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study   RedHill Biopharma Announces Positive PK Results in Support of Ongoing RHB-105 Phase III H. pylori Study – Hebrew

Read More...

RedHill Biopharma Announces First Patients Dosed in Phase III Study of RHB-105 for H. pylori Infection

RedHill Biopharma Announces First Patients Dosed in Phase III Study of RHB-105 for H. pylori Infection   RedHill Biopharma Announces First Patients Dosed in Phase III Study of RHB-105 for H. pylori Infection – Hebrew

Read More...

RedHill Biopharma Announces First Patient Dosed in Phase III Study of RHB-104 for Crohn’s Disease

RedHill Biopharma Announces First Patient Dosed in Phase III Study of RHB-104 for Crohn’s Disease   RedHill Biopharma Announces First Patient Dosed in Phase III Study of RHB-104 for Crohn’s Disease – Hebrew

Read More...

RedHill Biopharma Announces Positive Scientific Advice Meeting and European Marketing Application Strategy for RHB-103 (Migraine)

RedHill Biopharma Announces Positive Scientific Advice Meeting and European Marketing Application Strategy for RHB-103 (Migraine)   RedHill Biopharma Announces Positive Scientific Advice Meeting and European Marketing Application Strategy for RHB-103 (Migraine) – Hebrew

Read More...

RedHill Biopharma Reports Results for the Third Quarter of 2013

RedHill Biopharma Reports Results for the Third Quarter of 2013   RedHill Biopharma Reports Results for the Third Quarter of 2013 – Hebrew

Read More...

RedHill Biopharma Initiates Phase III Study of RHB-105 for H. pylori Infection

Redhill Biopharma Initiates Phase III Study of RHB-105 for H. pylori Infection   RedHill Biopharma Initiates Phase III Clinical Study with RHB-105 for H. pylori Infection – Hebrew

Read More...

RedHill Biopharma to Present at the 2013 Annual BioNetwork Conference

RedHill Biopharma to Present at the 2013 Annual BioNetwork Conference

Read More...

RedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 (H. pylori) Phase III Study

RedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 (H pylori) Phase III Study   RedHill Biopharma Announces FDA Acceptance of IND Application for RHB-105 (H pylori) Phase III Study – Hebrew

Read More...

RedHill Biopharma’s RHB-104 Combination Achieves 80% Remission in Independent Pediatric Crohn’s Study

RedHill Biopharma’s RHB-104 Combination Achieves 80% Remission in Independent Pediatric Crohn’s Study   RedHill Biopharma’s RHB-104 Combination Achieves 80% Remission in Independent Pediatric Crohn’s Study – Hebrew  

Read More...

RedHill Biopharma Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (anti-emetic)

RedHill Biopharma Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (anti-emetic)   RedHill Biopharma Reports Positive PK Clinical Studies Towards Planned NDA with RHB-102 (anti-emetic) – Hebrew

Read More...

RedHill Biopharma Initiates Phase III Study of RHB-104 for Crohn’s Disease

RedHill Biopharma Initiates Phase III Study of RHB-104 for Crohn’s Disease   RedHill Biopharma Initiates Phase III Study of RHB-104 for Crohn’s Disease – Hebrew

Read More...

RedHill Biopharma to Present at the Annual BioPharm America International Partnering Conference

RedHill Biopharma to Present at the Annual BioPharm America International Partnering Conference

Read More...

RedHill Biopharma Announces Positive Pre-Clinical Results for Lupus with RHB-104

RedHill Biopharma Announces Positive Pre-Clinical Results for Lupus with RHB-104

Read More...

RedHill Biopharma to Present at the Stifel Annual Healthcare Conference

RedHill Biopharma to Present at the Stifel Annual Healthcare Conference

Read More...

RedHill Biopharma Announces Positive European Regulatory Meetings Regarding its European Phase III Plan for RHB-104 (Crohn’s)

RedHill Biopharma Announces Positive European Regulatory Meetings Regarding its European Phase III Plan for RHB-104 (Crohn’s)   RedHill Biopharma Announces Positive European Regulatory Meetings Regarding its European Phase III Plan for RHB-104 (Crohn’s) – Hebrew

Read More...

RedHill Biopharma Announces Positive Pre-Clinical Rheumatoid Arthritis Results with RHB-104 and Plans for a Phase IIa Study

RedHill Biopharma Announces Positive Pre-Clinical Rheumatoid Arthritis Results with RHB-104 and Plans for a Phase IIa Study   RedHill Biopharma Announces Positive Pre-Clinical Rheumatoid Arthritis Results with RHB-104 and Plans for a Phase IIa Study – Hebrew

Read More...

RedHill Biopharma Reports Results for the Second Quarter of 2013

RedHill Biopharma Reports Results for the Second Quarter of 2013 (July 22 2013)   RedHill Biopharma Reports Results for the Second Quarter of 2013 (July 22 2013) – Hebrew

Read More...

RedHill Biopharma Provides Update on Planned NDA Filing for RHB-102 (Anti-Emetic) in Q1 2014

RedHill Biopharma Provides Update on Planned NDA Filing for RHB-102 (Anti-Emetic) in Q1 2014   RedHill Biopharma Provides Update on Planned NDA Filing for RHB-102 (Anti-Emetic) in Q1 2014 – Hebrew

Read More...

RedHill Biopharma to Present at JMP Securities Annual Healthcare Conference

RedHill Biopharma to Present at JMP Securities Annual Healthcare Conference

Read More...

RedHill Announces FDA Acceptance for Review of RHB-103 (Migraine) NDA and PDUFA Date

RedHill Announces FDA Acceptance for Review of RHB-103 (Migraine) NDA and PDUFA Date   RedHill Announces FDA Acceptance for Review of RHB-103 (Migraine) NDA and PDUFA – Hebrew

Read More...

RedHill Commences Patient Screening in a Phase IIa Clinical Trial with RHB-104 for Multiple Sclerosis

RedHill Commences Patient Screening in a Phase IIa Clinical Trial with RHB-104 for Multiple Sclerosis   RedHill Commences Patient Screening in a Phase IIa Clinical Trial with RHB-104 for Multiple Sclerosis (Hebrew)

Read More...

RedHill Biopharma Provides Update on RHB-101 (Cardio) FDA Meeting and a New Patent

RedHill Provides Update on RHB-101 (Cardio) FDA Meeting and a New Patent RedHill Provides Update on RHB-101 (Cardio) FDA Meeting and a New Patent – Hebrew

Read More...

RedHill Biopharma to Present at 2013 Jefferies Global Healthcare Conference

RedHill Biopharma to Present at 2013 Jefferies Global Healthcare Conference

Read More...

RedHill Biopharma Reports Financial Results for the First Quarter of 2013

RedHill Biopharma Reports Financial Results for the First Quarter of 2013 (May 2 2013)   RedHill Biopharma Reports Financial Results for the First Quarter of 2013 (May 2 2013) – Hebrew

Read More...

RedHill Biopharma Submits NDA for U.S. Marketing of RHB-103 Anti-Migraine Oral Thin Film

RedHill Biopharma Submits NDA for U S Marketing of RHB-103 Anti-Migraine Oral Thin Film   RedHill Biopharma Submits NDA for U S Marketing of RHB-103 Anti-Migraine Oral Thin Film – Hebrew

Read More...

RedHill Biopharma Provides Update on RHB-101 (Cardio) Scientific Advice Meeting and Planned Marketing Application Submission in Europe

RedHill Biopharma Provides Update on RHB-101 (Cardio) Scientific Advice Meeting and Planned Marketing Application Submission in Europe   RedHill Biopharma Provides Update on RHB-101 (Cardio) Scientific Advice Meeting and Planned Marketing Application Submission in Europe – Hebrew

Read More...

RedHill Biopharma to Present at the 25th Annual ROTH Conference – March 19 2013

RedHill Biopharma to Present at the 25th Annual ROTH Conference – March 19 2013

Read More...

RedHill Biopharma Provides Update on Development Progress and Planned NDA Submission for RHB-102 (oncology support, anti-emetic)

RedHill Biopharma Provides Update on Development Progress and Planned NDA Submission for RHB-102 (Feb 25 2013) – Hebrew RedHill Biopharma Provides Update on Development Progress and Planned NDA Submission for RHB-102 (Feb 25 2013)

Read More...

RedHill Biopharma reports 2012 fourth quarter and year-end results

RedHill Biopharma Reports 2012 Fourth Quarter and Year-End Results (February 19 2013)- Hebrew RedHill Biopharma Reports 2012 Fourth Quarter and Year-End Results (February 19 2013)  

Read More...

RedHill announces Notice of Allowance for US patent application relating to RHB-101 (Cardio)

RedHill Announces Notice of Allowance for US patent application – RHB-101 (Cardio)

Read More...

RedHill announces new patent and provides update on RHB-104 (Crohn’s)

RedHill announces new patent and provides update on RHB-104 (Crohn’s) RedHill announces new patent and provides update on RHB-104 (Crohn’s) – Hebrew

Read More...

RedHill announces NASDAQ listing and trading under the ticker “RDHL”

RedHill to commence NASDAQ listing and trading today under the ticker “RDHL” RedHill to commence NASDAQ listing and trading today under the ticker “RDHL” (Hebrew)

Read More...

RedHill announces successful completion of a private placement of approximately $6.5 million

RedHill Biopharma Announces Successful Completion of $6.5 Million Private Placement RedHill Biopharma Announces Successful Completion of $6.5 Million Private Placement (Hebrew)

Read More...

RedHill Announces Notice of Allowance for a new U.S. patent for RHB-104 (Crohn’s)

RedHill Announces Notice of Allowance for a new U.S. patent for RHB-104 (Crohn’s) RedHill Announces Notice of Allowance for a new U.S. patent for RHB-104 (Crohn’s) – Hebrew

Read More...

RedHill plans NDA filing with RHB-103 (migraine) following positive pre-NDA meeting on Nov. 7th with FDA

RedHill plans NDA filing with RHB-103 (migraine) after positive Pre-NDA meeting with FDA

Read More...

RedHill to initiate PIIa Multiple Sclerosis study with RHB-104 following positive pre-clinical studies

RedHill to initiate PII Multiple Sclerosis study with RHB-104 following positive pre-clinical studies RedHill to initiate PII Multiple Sclerosis study with RHB-104 after positive pre-clinical results (Hebrew)

Read More...

RedHill Biopharma filed a registration statement for NASDAQ listing

RedHill Biopharma filed a registration statement for NASDAQ listing (Sept 13 2012) RedHill Biopharma filed ADR listing documents on NASDAQ (Sept 13, 2012) – (Hebrew)

Read More...

RedHill Biopharma announces successful pivotal bioequivalence trial results with RHB-103 (migraine)

RedHill announces successful pivotal BE trial results with RHB-103 (Migraine) (May 28 2012) RedHill announces successful pivotal BE trial results with RHB-103 (Migraine) – Hebrew – (May 28 2012)

Read More...

RedHill Biopharma commenced advanced clinical trial with RHB-103 (migraine)

RedHill Biopharma commenced advanced clinical trial with RHB-103 (Migraine) (April 24 2012) English   RedHill Biopharma commenced advanced clinical trial with RHB-103 (Migraine) (April 24 2012) Hebrew

Read More...

RedHill Biopharma announces successful pivotal bioequivalence trial results with RHB-102 (prevention of nausea and vomiting)

RedHill announces successful pivotal BE trial results with RHB-102 (nausea and vomiting) – April 17, 2012 RedHill announces successful pivotal BE trial results with RHB-102 (nausea and vomiting) – Hebrew – April 17, 2012 See Dror Ben Asher (CEO) and Gilead Raday’s (VP Product Development) TV interview regarding RHB-102 trial results (Hebrew): http://www.bizportal.co.il/shukhahon/biznews02.shtml?mid=315186&strsrh=רדהיל    

Read More...

RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) featured by the Israeli Ministry of Foreign Affairs

http://www.mfa.gov.il/MFA/InnovativeIsrael/No-more-nausea-after-chemo-1-Mar-2012

Read More...

RedHill Biopharma’s RHB-102 (prevention of nausea and vomiting) advanced clinical trial has began

RedHill Biopharma commences advanced clinical trial with RHB-102 (Nausea and Vomiting) (February 14 2012) RedHill Biopharma commenced advanced clincial trial with RHB-102 (Nausea and Vomiting) (February 14 2012) Hebrew

Read More...

RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (prevention of nausea and vomiting)

RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Nausea and Vomiting) Feb 12th 2012 RedHill Biopharma obtains FDA IND for advanced clinical trial with RHB-102 (Nausea and Vomiting) Feb 12th 2012 (Hebrew)

Read More...

RedHill Biopharma obtains a CTA approval from Health Canada to commence an advanced trial with RHB-102 (prevention of nausea & vomiting)

RedHill Biopharma obtains a CTA approval to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) (February 5th 2012) RedHill Biopharma obtains a CTA approval to commence an advanced trial with RHB-102 (prevention of nausea & vomiting) (February 5th 2012) Hebrew

Read More...

Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients)

See Mr. Gilead Raday’s interview on Israel21c, regarding RHB-102 (prevention of nausea & vomiting in cancer patients): http://israel21c.org/health/daily-pill-to-vanquish-nausea-after-chemo

Read More...

IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial

IntelGenx, RedHill’s Development Partner in RHB-103 (Migraine) Announces Health Canada Approval for Pivotal Trial

Read More...

Dr. Jeff Lehighton presents RedHill Biopharma on Bloomberg TV

Please use the link below to watch Dr. Jeff Lehighton, RedHill Biopharma’s Chairman of the Advisory Board, on Bloomberg TV: http://www.bloomberg.com/video/80653140/

Read More...

RedHill Biopharma engages with CRO for potential pivotal trial with RHB-102 (prevention of nausea & vomiting in cancer patients)

RedHill engages with CRO for potential pivotal trial with RHB-102 (Prevention of Nausea Vomiting ) (Hebrew) RedHill engages with CRO in preparation for potential pivotal trial with RHB-102 (prevention of nausea & vomiting )

Read More...

RedHill Biopharma appoints Prof. Colm O’Morain, MD as Lead Investigator for the European Phase III trial with RHB-104 (Crohn’s)

RedHill appoints Prof O’Morain as Lead Investigator for the European Phase III clinical trial with RHB-104 (Crohn’s) Hebrew Redhill appoints Prof O’Morain as Lead Investigator for the European Phase III trial with RHB-104 – Crohn’s (October 24 2011)

Read More...

RedHill Biopharma appoints Prof. David Y. Graham, MD as Lead Investigator for the US pivotal trial with RHB-104 (Crohn’s)

RedHill Biopharma appoints Prof Graham as Lead Investigator for RHB-104 – Crohn’s (Hebrew) (October 5, 2011) RedHill Biopharma appoints Prof Graham as Lead Investigator for the US pivotal trial with RHB-104 – Crohn’s (October 5, 2011)

Read More...

RedHill Biopharma Acquires Exclusive Rights to a MAP Bacterium Companion Diagnostic Test for its RHB-104 (Crohn’s)

RedHill acquires exclusive rights to a diagnostic test for RHB-104 – Crohn’s (Sep. 19 2011)

Read More...

IntelGenx and RedHill Sign a Binding Term-Sheet for an Anti-Psychotic Film Product

IntelGenx Announces Licensing of Anti-Psychotic VersaFilm Product

Read More...

RedHill Biopharma Appoints Advisory Board Headed by Dr. Jeff Leighton

RedHill Biopharma Appoints Advisory Board (Hebrew) (April 3rd 2011) RedHill Biopharma Appoints Advisory Board (English) (April 3rd 2011)

Read More...

RedHill Appoints Teva’s Former CFO, Dan Suesskind, as Director

RedHill appoints Teva’s former CFO, Dan Seusskind, as Director (English) (Feb. 22, 2011) RedHill appoints Teva’s former CFO, Dan Seusskind, as Director (Hebrew) (Feb. 22, 2011)

Read More...

RedHill Biopharma Announces Successful IPO on the Tel Aviv Stock Exchange

RedHill Biopharma Announces Successful IPO (English)(Feb. 7, 2011) RedHill Biopharma Announces Successful IPO (Hebrew)(Feb. 4, 2011)

Read More...

Tel Aviv Stock Exchange Ticker and ISIN Details: Share and Warrant

Share and Warrant Ticker and ISIN Details

Read More...

RedHill Announces Successful Completion of $10m Financing – 3 Times More than Originally Planned

Completion of Financing (Nov. 5, 2010) (IN ENGLISH) Completion of Financing (Nov. 3, 2010) (IN HEBREW)

Read More...

IntelGenx Exhibits VersaFilm Triptan (RHB-103) Poster at CPhl Paris

VersaFilm-Poster CPhI Oct. 2010 Paris

Read More...

RedHill Biopharma Raises $3.5M in a Private Placement

RedHill Biopharma Raises $3.5M in a Private Placement The Company Reports the Closing of Two Transactions and the Possibility of an IPO Tel Aviv, September 12, 2010 – RedHill Biopharma Ltd, an Israeli biopharmaceutical company, has completed the first part of a private placement, raising $3.5 million dollars. The Company also reports the final closing […]

Read More...

Giaconda Completes Sale of 3 Products to RedHill Biopharma

 GIACONDA COMPLETES SALE OF MYOCONDA, HELICONDA AND PICOCONDA Sale of patents brings significant cash injection into Giaconda Giaconda stands to benefit if the patents are successfully commercialised Sydney, NSW, 31 August 2010 – Giaconda Limited (ASX:GIA) (the “Company”) today announced that it has completed the sale of its Myoconda, Heliconda and Picoconda patents to RedHill […]

Read More...

IntelGenx and RedHill Announce Definitive Agreement

 IntelGenx and RedHill Announce Definitive Agreement for Anti-Migraine Film Product  SAINT LAURENT, QUEBEC–(Marketwire – Aug. 30, 2010) – IntelGenx Corp. (TSX VENTURE:IGX)(OTCBB:IGXT) (“IntelGenx”) and RedHill Biopharma Ltd., an Israeli corporation (“RedHill”) today announced that they have entered into a co-development and commercialization agreement for IntelGenx’ first oral thin film product based upon the IntelGenx’ proprietary […]

Read More...

SCOLR Pharma and RedHill Biopharma enter into Licensing Agreement

BOTHELL, WA, May 6, 2010, – SCOLR Pharma, Inc. (NYSE AMEX: DDD) today announced that it has executed a Licensing Agreement with RedHill Biopharma Ltd. an Israeli corporation [...]

Read More...

Egalet and RedHill Biopharma enter into License Agreement

Egalet and RedHill Biopharma enter into an exclusive license agreement to develop, and commercialize Egalet’s EG-P042 (Carvedilol) for the treatment of certain cardiac diseases [...]

Read More...

News